CRISPR Therapeutics announced the appointment of Alex Harding, M.D., M.B.A., as Senior Vice President, SVP, and Head of Business Development, effective January 5, 2023. Dr. Harding brings extensive leadership experience in biopharma business development and corporate strategy and joins CRISPR Therapeutics to lead the Company’s business development operations. Dr. Harding most recently served as Senior Vice President of Business Development and Corporate Strategy at Remix Therapeutics.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRSP:
- CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business Development
- Crispr Therapeutics provides update on ongoing Phase 1 CARBON trial
- CRISPR Therapeutics Provides Update on Its Ongoing Phase 1 CARBON™ Trial of CTX110®
- Oppenheimer emerging biotech analysts to hold analyst/industry conference call
- CRISPR Therapeutics to Present at the 2022 BMO Growth & ESG Conference
